BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) (the “Company” or “RegeneRx”) announced today that it received an Australian patent covering certain compositions and methods for delivery of Thymosin beta 4 (Tß4), its analogues, isoforms and other derivatives for increasing the local concentration of such compounds at wounded or injured sites in the body. The patent expires in 2024.